

Quarterly Statement

as of September 30, 2026




MEDIOS

Key financials (IFRS)




€ 1,633 million

Revenue



€ 66.7 million

EBITDA, adjusted for special items[1]



€ 26.2 million

Cash flow from operating activities

		9M 2026	9M 2025	Δ in %	Q3 2026	Q3 2025	Δ in %
Revenue	**€ thousand**	**1.633.038**	**1.529.997**	**6,7**	**558.108**	**538.285**	**3,7**
EBITDA	**€ thousand**	**57.020**	**63.634**	**–10,4**	**18.467**	**21.439**	**–13,9**
Margin (in % of revenue)	%	3,5	4,2	–0,7 PP	3,3	4,0	–0,7 PP
EBITDA, adjusted for special items[1]	**€ thousand**	**66.667**	**70.351**	**–5,2**	**22.705**	**24.020**	**–5,5**
Margin (in % of revenue)	%	4,1	4,6	–0,5 PP	4,1	4,5	–0,4 PP
EBIT	**€ thousand**	**27.755**	**35.218**	**–21,2**	**9.118**	**11.855**	**–23,1**
Margin (in % of revenue)	%	1,7	2,3	–0,6 PP	1,6	2,2	–0,6 PP
Consolidated earnings after tax	**€ thousand**	**12.771**	**19.912**	**–35,9**	**4.263**	**7.228**	**–41,0**
Earnings per Share	**€**	**0,52**	**0,79**	**–34,0**	**0,17**	**0,29**	**–41,4**
Adjusted earnings per share[2]	**€**	**1,35**	**1,50**	**–10,0**	**0,48**	**0,55**	**–12,7**
Cash flow from operating activities	**€ thousand**	**26.221**	**52.664**	**–50,2**	**15.035**	**29.299**	**–48,7**
Investments (CapEx)	€ thousand	10.318	4.716	>100,0	2.207	1.832	20,5
Free Cash Flow (excluding M&A)[3]	€ thousand	15.902	47.948	–66,8	12.828	27.467	–53,3
		09/30/2026	12/31/2025				
Total assets	**€ thousand**	**932,241**	**903,041**	**3.2**			
Equity	€ thousand	528,111	514,219	2.7			
Equity Ratio	%	56.6	56.9	–0.3 PP			
Debt-to-Equity Ratio		**1.2**	**1.3**	**–7.7**			
Employees	**Number**	**960**	**999**	**–3.9**			

		9M 2026	9M 2025	Δ in %	Q3 2026	Q3 2025	Δ in %
1 Special items	**€ thousand**	**9,647**	**6,717**	**43.6**	**4,238**	**2,581**	**64.2**
Expenses from Stock Option Programs	€ thousand	735	632	16.3	245	211	16.1
Other Expenses M&A	€ thousand	988	894	10.5	657	879	–25.3
ERP Implementation costs	€ thousand	4,795	3,781	26.8	1,962	1,379	42.3
Restructuring Costs	€ thousand	2,685	0	n/a	1,152	0	n/a
One-time special expenses related to the change in the Executive Board	€ thousand	444	1,410	–68.5	222	112	98.2


		9M 2026	9M 2025	Δ in %	Q3 2026	Q3 2025	Δ in %
2 Earnings per share adjusted							
Earnings after taxes	€ thousand	12,771	19,912	–35.9	4,263	7,228	–41.0
Special items	€ thousand	9,647	6,717	43.6	4,239	2,581	64.2
Acquisition-related PPA[4] depreciation and amortization	€ thousand	17,893	18,224	–1.8	5,964	6,075	–1.8
Adjustment for taxes on restatements	€ thousand	–7,108	–7,049	0.8	–2,628	–2,426	8.3
Adjusted earnings after taxes	€ thousand	33,203	37,804	–12.2	11,838	13,458	–12.0
Weighted average number of shares	Number	24,517,656	25,229,988	–2.8	24,519,361	24,681,547	–0.7
Earnings per share adjusted for special items	€	1.35	1.50	–10.0	0.48	0.55	–12.7

3 Calculated from cash flow from operating activities less capital expenditure (CapEx).
4 PPA: Purchase Price Allocation.

Revenue by operating segment

International Business
€129.3 million
8.0%

Patient-specific therapies
€180.0 million
11.0%




Pharmaceutical supply
€1,323.5 million
81.0%

EBITDA by operating segment, adjusted for special items[1]

International Business
€20.3 million
27.7%

Patient-specific therapies
€17.7 million
24.1%



Pharmaceutical supply
€35.3 million
48.2%

Quarterly statement as of September 30, 2026

MEDIOS AG ACHIEVES SOLID REVENUE GROWTH; OPERATING INCOME IN LINE WITH EXPECTATIONS DESPITE A CHALLENGING ENVIRONMENT

- Consolidated revenue rises by 6.7% to €1,633.0 million in the first nine months of 2026; growth driven by all operating segments
- EBITDA pre stands at €66.7 million (9M 2025: €70.4 million), with a margin of 4.1% (9M 2025: 4.6%)
- Operating cash flow amounts to €26.2 million (9M 2025: €52.7 million)
- Consistent implementation of the "Avanti Medios!" efficiency program is showing results
- New "Medios Next Level" strategy presented at Capital Markets Day
- Caelo acquisition completed; integration underway
- Full-year forecast confirmed; EBITDA pre expected at the lower end of the range

SIGNIFICANT EVENTS

Entry into the medical cannabis market

The Medios Group expanded its product portfolio at the beginning of the 2026 financial year and entered the medical cannabis market. In doing so, it adds a therapeutically important option to its existing indication areas.

Medios' entry into the medical cannabis market took place amid an increasingly uncertain regulatory environment. This particularly concerns the reimbursability by statutory health insurers. Since July 30, 2026, cannabis flowers may no longer be prescribed at the expense of statutory health insurers. As a result, the uncertainty regarding the future revenue potential has increased.

Change in the Finance department: Stefan Bauerreis succeeds Falk Neukirch

On March 26, 2026, the Supervisory Board of Medios AG announced that it had appointed Stefan Bauerreis as a member of the Executive Board and as the company's new Chief Financial Officer (CFO), effective April 15, 2026. Stefan Bauerreis succeeds Falk Neukirch, who – as announced on March 6, 2026 – left the Medios Group at his own request.

With the appointment of Stefan Bauerreis, Medios has gained an experienced finance expert with many years of international leadership experience in industry and at publicly traded companies. Among other roles, he served as Chief Financial Officer of the Stabilus Group and held various senior finance positions within the Schaeffler Group for more than two decades, including as CFO for the region Europe and Germany. Stefan Bauerreis possesses extensive expertise in the classic finance functions of accounting, controlling, tax, and financing, as well as in the areas of IT, M&A, and the transformation and management of international companies.

Constantijn van Rietschoten's contract extended early

In June, the Supervisory Board of Medios AG ("Medios") decided to extend the existing Executive Board contract of Constantijn van Rietschoten (Chief Business Officer International, CBO International) early by an additional three years, through April 30, 2030. Constantijn van Rietschoten has been a member of the Executive Board of Medios AG since May 1, 2024, and was appointed for a three-year term ending April 30, 2027. His area of responsibility includes, in particular, the International Business segment and its strategic development.

Optimization of the compounding network

On June 29, 2026, Medios AG announced the closure of the facility operated by its wholly-owned subsidiary, Medios Solutions Aschaffenburg GmbH. With this move, Medios is consolidating patient-specific compounding at the remaining locations within its Germany-wide network, thereby ensuring that pharmacies and clinics continue to be supplied. Aschaffenburg most recently accounted for approximately 10% of the compounding volume of the Medios Group's German production facilities.

Christoph Prusseit will step down from his Executive Board mandate after his current term of office

Christoph Prusseit, a Member of the Executive Board of Medios AG and Chief Business Officer Germany, informed the Supervisory Board in September 2026 that, for personal reasons, he will not be available for an extension of his contract, which expires on July 31, 2027. He will continue to fulfill his responsibilities for the German business as usual until the end of the year and ensure an orderly transition. Thereafter, he will continue to serve the company in an advisory capacity.

Ambition 2031: €3.1 billion in revenue and a doubling of adjusted EBITDA

On September 29, 2026, at its Capital Markets Day in Breda, the Netherlands, the Medios Group presented its "Medios Next Level" strategy and its 2031 Ambition. The strategy repositions Medios from a Specialty Pharma company to a focused pharmaceutical services group with two operating segments starting in 2027: Specialty Pharma Supply and Compounding. It is based on four pillars – operational excellence, organic growth, international expansion in compounding, and selective, value-enhancing M&A. The goals are profitable growth, strong cash generation, and a higher-quality earnings mix. By 2031, Medios aims to achieve consolidated revenue of approximately €3.1 billion; at the same time, adjusted EBITDA is expected to double to around €170 million, and the adjusted EBITDA margin is projected to reach 5.5%.

Medios acquires Caelo and strengthens its European compounding essentials business

On October 1, 2026, Medios AG completed the acquisition of 74% of the shares in Caesar & Loretz GmbH (Caelo) after receiving the necessary antitrust approval. Options have been agreed upon for the acquisition of the remaining 26% of the shares. Medios will consolidate its European Compounding Essentials business under Medios Holding Compounding Essentials GmbH.

POSITION OF THE MEDIOS GROUP

Earnings position of the Medios Group (IFRS)

The Medios Group's revenue increased by €103.0 million, or 6.7%, to €1,633.0 million in the first nine months of the 2026 financial year compared to the same period in the previous year (€1,530 million).

The Pharmaceutical Supply segment generated external revenue of €1,323.5 million during the reporting period (9M 2025: €1,239.5 million), representing an increase of €84.0 million, or 6.8%, compared to the prior-year period, driven primarily by higher revenue in the wholesale business.

Revenue in the Patient-Specific Therapies segment increased by €13.9 million, or 8.4%, compared to the same period in the previous year, to €180.0 million (9M 2025: €166.0 million) driven by rising production volumes across all customer segments, thereby also making an above-average contribution to the increase in consolidated revenue.

The International Business segment increased its revenue in the first nine months of the 2026 financial year to €129.3 million (9M 2025: €124.2 million), which was €5.1 million, or 4.1%, higher than the figure for the same period in the 2025 financial year.

In the Services segment, external revenue remained low at €0.4 million.

The Group's gross profit for the reporting period amounted to €151.6 million, which was €0.1 million, or 0.1%, higher than the figure for the same period in the previous year (€151.5 million). The gross profit margin decreased by 0.6 percentage points to 9.3% (prior year: 9.9%), primarily due to price declines for selected products in the Pharmaceutical Supply and Patient-Specific Therapies segments, as well as a temporary increase in material costs in the International Business segment.

In the Pharmaceutical Supply segment, gross profit decreased by approximately €2.2 million to €49.4 million (9M 2025: €51.6 million), representing a decline of about 4.3%. At 3.4%, the gross profit margin was below the level of the prior-year period (9M 2025: 3.8%). This decline is primarily attributable to temporary price reductions in certain product areas driven by market conditions, although initial improvements began to materialize in September.

The Patient-Specific Therapies segment increased its gross profit in the first nine months of the 2026 financial year by approximately €0.6 million, or 1.4%, to €42.8 million (9M 2025: €42.2 million). The gross profit margin decreased by 1.0 percentage points to 22.9% during the same period (9M 2025: 23.9%) – primarily as a result of regulatory actions to control prices in the German pharmaceutical market, which have been in effect since November 2025.

The International Business segment increased its gross profit during the reporting period by approximately €1.6 million, or 2.8%, to €58.8 million (9M 2025: €57.2 million). At 45.4%, the gross profit margin was approximately 0.6 percentage points below the prior-year level (9M 2025: 46.0%). While operating performance remained stable, comparability with the prior-year period is affected by the one-time positive impact on earnings from the sale of a pharmacy in the first quarter of 2025.

The Group's personnel expenses totaled €54.2 million in the first nine months of the 2026 financial year (9M 2025: €51.7 million). The increase of €2.5 million compared with the prior year was primarily attributable to higher personnel expenses resulting from the closure of the Aschaffenburg site and the restructuring of a Belgian subsidiary, as well as to increased expenses for equity-based compensation programs.

Other operating expenses amounted to €40.4 million in the reporting period (9M 2025: €36.2 million). The €4.2 million increase compared with the same period in the previous year was primarily due to higher IT expenses related to the implementation of SAP S/4HANA, higher expenses for temporary staff, increased facility costs, and higher M&A expenses.

Despite positive revenue growth, the Group's EBITDA declined by €6.6 million, or 10.4%, compared to the comparable period in the previous year. Material factors contributing to this decline were the lower gross profit margin and the increase in operating expenses, which more than offset the positive effect of revenue growth. EBITDA is reconciled to the Group's earnings before interest, taxes, and depreciation and amortization (EBITDA pre), adjusted for special items, as follows:

in € thousand	9M 2026	9M 2025
EBITDA	**57,020**	**63,634**
Expenses from Stock Option Programs	735	632
Other M&A expenses	988	894
ERP implementation costs	4,795	3,781
Restructuring costs	2,685	0
One-time special expenses in connection with the change in the Executive Board	444	1,410
EBITDA pre[1]	**66,667**	**70,351**

1 Adjusted for special items

The Pharmaceutical Supply segment contributed an EBITDA pre of €35.3 million (9M 2025: €38.8 million) to consolidated EBITDA pre. The decline of €3.5 million, or 9.1%, compared to the same period in the previous year is primarily attributable to price reductions on selected products in the first nine months of the 2026 financial year. These had a negative impact on earnings performance, meaning that revenue growth was not reflected to the same extent in EBITDA pre.

EBITDA pre for the Patient-Specific Therapies segment, adjusted for special items, decreased by €0.4 million, or 2.3%, compared to the prior year to €17.7 million (9M 2025: €18.1 million). Earnings performance was influenced by a lower gross profit margin and higher operating expenses, causing EBITDA pre to remain below the prior-year level despite revenue growth. Regulatory actions for price control in the German pharmaceutical market, which have been in effect since November 2025, an unfavorable product mix, and one-time effects from back payments of ancillary costs from prior years had a negative impact on earnings performance. In the second and third quarters of 2026, actions to enhance operational excellence had a positive impact. These included the closure of the Aschaffenburg site with the transfer of customers to other laboratories, increased capacity utilization and efficient cost management, as well as the discontinuation of the Advanced Therapies segment.

The International Business segment contributed €20.3 million in EBITDA pre (9M 2025: €22.0 million) to consolidated EBITDA pre. This represents a decrease of €1.7 million, or 7.7%, compared with the same period in the previous year. In particular, the higher business volume resulting from the acquisition of new customers and the expansion of the product portfolio had a positive impact on earnings. Conversely, temporarily higher material costs related to eye injections and increased personnel expenses resulting from salary adjustments had a negative impact on earnings performance. In addition, there was a portfolio effect resulting from the sale of all shares in Groot Driene V.O.F. as of February 28, 2025, in Clindia Benelux B.V. as of July 1, 2025, and in the companies Apotheek Bierhaalder B.V. and Apotheek Groenendaal B.V. as of October 31, 2025. The EBITDA contributions from these companies were still included in the prior-year period up until their respective disposals. In the 2026 financial year , they no longer contributed to consolidated earnings.

EBITDA pre for the Services segment improved by approximately €1.9 million, or 22.7%, to €–6.6 million in the first nine months of 2026 (9M 2025: €–8.6 million)

Depreciation and amortization totaled €29.3 million in the first nine months of the 2026 financial year (9M 2025: €28.4 million). In addition to scheduled depreciation and amortization of property, plant and equipment and intangible assets, this figure includes, in particular, scheduled acquisition-related PPA[1] depreciation and

1 Purchase Price Allocation

amortization of €17.9 million (9M 2025: €18.2 million) and depreciation of capitalized rights-of-use from leases of €3.9 million (9M 2025: €4.0 million). Additionally, the figure includes non-scheduled impairments of long-term assets related to the closure of the Aschaffenburg site totaling €0.9 million (9M 2025: €0).

The Medios Group's financial result improved by €2.7 million compared to the same period in the previous year, to €–4.6 million (9M 2025: €–7.3 million). This was primarily due to lower financial expenses, which resulted from a reduced loan portfolio following the scheduled repayment of the term loan. Positive fair value changes in derivative financial instruments also led to higher financial income compared to the same period in the previous year.

Despite the lower pre-tax profit, tax expense increased compared with the same period in the previous year, primarily due to offsetting non-recurring effects from prior periods. While the tax rate in the prior-year period was reduced by non-recurring tax income of €0.4 million, in the current reporting period, non-recurring tax expenses and higher non-tax-deductible expenses related to the closure of the Aschaffenburg site led to an increase in the tax rate to 44.9% (9M 2025: 28.6%).

Net income after taxes for the first nine months of 2026 was €12.8 million, below the prior-year level (9M 2025: €19.9 million).

Earnings per share accordingly amounted to €0.52 (9M 2025: €0.79), representing a decline of 34.0%. By contrast, adjusted earnings per share, at €1.35 (9M 2025: €1.50), were approximately 10.0% below the prior-year level.

Financial position of the Medios Group (IFRS)

Cash and cash equivalents totaled €92.2 million as of September 30, 2026, representing an increase of €10.4 million compared to the figure as of December 31, 2025 (€81.8 million). They consisted primarily of freely available bank balances and, to a lesser extent, of overdraft facilities. The increase of €10.4 million compared with the end of 2025 is primarily attributable to the following cash flows:

Cash flow from operating activities amounted to €26.2 million in the first nine months of the 2026 financial year (9M 2025: €52.7 million), representing a decrease of €26.4 million, or 50.2%, compared with the prior-year figure. The main drivers of this development were the significantly stronger year-over-year increase in working capital, which was associated with higher tied-up funds; tax payments that were approx. €5.3 million higher; and the decline in consolidated net income by approx. €7.1 million.

Cash flow from investment activities amounted to €–7.9 million (9M 2025: €–2.3 million). The increase in cash outflows of approximately €5.6 million is primarily attributable to higher payments for Investments in fixed assets totaling approximately €8.4 million (9M 2025: €3.6 million). The majority of the increase resulted from investments related to the construction of a new warehouse in the Netherlands, as well as from higher investments in hardware and software. In contrast, proceeds from the disposal of intangible assets and property, plant and equipment totaling €1.6 million (9M 2025: €0.6 million) had a positive effect on cash flow from investment activities.

Cash flow from financing activities amounted to €–7.9 million in the first nine months of the 2026 financial year (prior year: €–63.0 million). It primarily resulted from cash inflows from the net drawdown of additional tranches under the revolving credit facilities (RCF) of €20.0 million (prior year: net repayment of €20.0 million). This was offset by cash outflows, primarily from the scheduled repayment of the term loan in the amount of €18.8 million (9M 2025: €18.8 million), from interest paid in the amount of €5.1 million (9M 2025: €7.7 million) related to the utilized credit facilities, and repayments of lease liabilities of €3.9 million (9M 2025: €3.8 million).

Net assets of the Medios Group (IFRS)

The Group's balance sheet total as of September 30, 2026, increased by approximately €29.2 million compared to December 31, 2025, to €932.2 million (December 31, 2025: €903.0 million).

Intangible assets decreased by a total of €17.7 million compared to December 31, 2025 – primarily due to scheduled depreciation and amortization of customer bases and other intangible assets.

The carrying amounts of property, plant and equipment increased by €2.1 million compared to December 31, 2025, to €43.1 million, as investments exceeded scheduled depreciation. Capitalized rights-of-use from leases decreased compared to the end of the previous year, primarily due to scheduled depreciation and amortization.

Short-term assets increased by €48.7 million to €392.3 million as of the balance sheet date (December 31, 2025: €343.7 million). This development is primarily attributable to an increase in trade receivables (+€36.9 million) as of the balance sheet date. Income tax receivables, however, decreased by €3.5 million to €4.9 million (December 31, 2025: €8.4 million).

Shareholders' equity amounted to €528.1 million as of September 30, 2026, representing an increase of €13.9 million compared with the end of 2025 (December 31, 2025: €514.2 million). As part of an equity-based compensation payment, treasury shares were transferred to a Member of the Executive Board. As a result, the deduction for treasury shares in equity decreased by €0.2 million to €–12.4 million as of the balance sheet date (December 31, 2025: €12.6 million). The equity ratio stood at approximately 56.7% as of September 30, 2026 (December 31, 2025: 56.9%).

Long-term liabilities decreased by €38.6 million as of the balance sheet date to €169.0 million (December 31, 2025: €207.5 million). This was primarily due to the scheduled repayment of the term loan in the amount of €18.8 million, the reduction in leasing liabilities by €3.7 million, and the decrease in deferred tax liabilities by €5.1 million. In addition, liabilities to minority shareholders totaling €11.3 million were reclassified from Long-term to Short-term financial liabilities due to the remaining term of less than twelve months as of the balance sheet date.

Short-term liabilities increased by €53.9 million compared with December 31, 2025, to €235.2 million (December 31, 2025: €181.3 million). This was primarily due to a reporting-date-related increase in trade payables of €17.8 million, the reclassification of liabilities to minority shareholders with a remaining term of less than twelve months in the amount of €11.3 million, and the new issuance of a Short-term bridge loan for the proportional acquisition of Caesar & Loretz GmbH with a one-year term in the amount of €20.0 million.

Outlook for the 2026 financial year

The Executive Board revised its forecast on July 28, 2026 and now expects revenue to range from €2.1 billion to €2.16 billion (previously: €2.0 billion to €2.12 billion) and EBITDA pre to range from €88 million to €92 million (previously: €94 million to €102 million).

The adjustment to the earnings forecast was primarily due to the ongoing decline in prices for high-margin products in the Pharmaceutical Supply segment, as well as to a deterioration in the business outlook for the Medical Cannabis division as a result of the Statutory Health Insurance Contribution Rate Stabilization Act. In addition, business performance in the International Business segment in the second half of 2026 was expected to fall slightly short of previous expectations.

Medios expects that the adjustment to the auxiliary tax in Germany, which has since been enacted, will weigh on the margin in the compounding business (Patient-Specific Therapies segment). As a result, the negative impact on EBITDA pre in the fourth quarter will amount to approx. €1.2 million. However, the Executive Board continues to assume that the earnings forecast adjusted in the summer can be achieved, even if earnings are expected to be toward the lower end of the defined range for EBITDA pre.

The forecast continues to be based on a number of assumptions regarding the future business development of the Medios Group. However, should key assumptions not materialize or should economic conditions change significantly, a further adjustment to the forecast cannot be ruled out.

Events after the balance sheet date

On October 1, 2026, the acquisition of 74% of the shares in Caesar & Loretz GmbH was closed, and the company was fully consolidated for the first time as of that date. With the acquisition of Caelo, the market leader for Compounding Essentials (API) in Germany, the Medios Group gains strong access to the German market and, together with its subsidiaries Magis-Pharma N.V. (Belgium) and Metapharmaceutical Industrial SL (Spain), can significantly expand its European footprint.

Consolidated statement of comprehensive income

in € thousand	9M 2026	9M 2025	Δ in %
Revenue	**1,633,038**	**1,529,997**	**6.7**
Change in stocks of finished goods and work-in-progress	2,331	715	>100
Other own work capitalized	228	0	n/a
Other Income	2,332	3,171	–26.5
Cost of materials	1,486,334	1,382,376	7.5
Personnel expenses	54,195	51,718	4.8
Other Expenses	40,380	36,156	11.7
Earnings before interest, tax, depreciation and amortization	**57,020**	**63,634**	**–10.4**
Depreciation and amortization	29,265	28,417	3.0
Operating profit/loss	**27,755**	**35,218**	**–21.2**
Financial expenses	5,702	7,875	–27.6
Financial income	1,107	559	98.0
Financial result	–4,595	–7,316	–37.2
Consolidated earnings before tax	**23,160**	**27,901**	**–17.0**
Income taxes	10,389	7,989	30.0
Consolidated earnings after tax	**12,771**	**19,912**	**–35.9**
Total consolidated earnings			
Undiluted earnings per share (in €)	0.52	0.79	–34.0
Diluted earnings per share (in €)	0.52	0.79	–34.0

Consolidated balance sheet

Assets

in € thousand	09/30/2026	12/31/2025	Δ in %
Non-current assets	**539,933**	**559,385**	**–3.5**
Intangible assets	466,929	484,643	–3.7
Property, plant and equipment	43,151	41,024	5.2
Rights of Use as a Lessee	28,346	32,029	–11.5
Financial assets	1,506	1,690	–10.9
Current assets	**392,309**	**343,657**	**14.2**
Inventories	97,774	93,318	4.8
Trade receivables	179,595	142,713	25.8
Current Financial Assets	1,674	884	89.4
Other assets	16,092	16,097	0.0
Income Tax Receivables	4,934	8,445	–41.6
Cash and cash equivalents	92,239	81,844	12.7
Non-current assets held for sale	0	355	–100.0
Total assets	**932,241**	**903,041**	**3.2**

Liabilities

in € thousand	09/30/2026	12/31/2025	Δ in %
Equity			
Subscribed Capital	25,506	25,506	0.0
Capital reserve	408,475	407,525	0.2
Accumulated consolidated net income	106,539	93,768	13.6
Treasury shares	–12,409	–12,580	–1.4
Attributable to shareholders in the parent company	**528,111**	**514,219**	**2.7**
Liabilities			
Non-current liabilities	**168,956**	**207,514**	**–18.6**
Financial liabilities	136,625	170,186	–19.7
Other accrued liabilities	4,206	4,099	2.6
Deferred tax liabilities	28,125	33,230	–15.4
Current Liabilities	**235,174**	**181,308**	**29.7**
Other provisions	1,919	1,779	7.9
Trade payables	108,190	90,423	19.6
Financial liabilities	61,343	31,604	94.1
Income tax liabilities	36,262	32,128	12.9
Other liabilities	26,705	24,999	6.8
Advance payments received	755	375	>100
Total Liabilities	**404,130**	**388,822**	**3.9**
Total assets	**932,241**	**903,041**	**3.2**

Consolidated statement of cash flows

in € thousand	9M 2026	9M 2025	Δ in %
Cash flow from operating activities			
Consolidated net income after tax	12,771	19,912	–35.9
Depreciation and amortization	29,265	28,417	3.0
Decrease/Increase in provisions	139	–106	<–100
Other non-cash expenses	1,009	632	59.7
Increase in inventories, trade receivables, and other assets not attributable to investments or financing activities	–41,620	–45,109	–7.7
Decrease/increase in trade payables and other liabilities not attributable to investing or financing activities	18,193	38,193	–52.4
Financial result	4,595	7,317	–37.2
Income/losses on the disposal of assets	–671	–2,059	–67.4
Income tax expense	10,389	7,989	30.0
Income tax payments	–7,849	–2,522	>100
Net Cash inflow from operating activities	**26,221**	**52,664**	**–50.2**
Cash flow from investment activities			
Payments for investments in intangible assets	–1,943	–1,079	80.1
Proceeds from disposals of intangible assets	170	23	>100
Payments for investments in property, plant, and equipment	–8,375	–3,637	>100
Proceeds from disposals of property, plant, and equipment	1,395	626	>100
Proceeds from disposals of long-term financial assets	197	191	3.1
Payments for investments in non-current financial assets	–14	–13	7.7
Payments for additions to the scope of consolidation	0	–2,328	–100.0
Proceeds from disposals from the scope of consolidation	3	3,365	–99.9
Interest received	655	559	17.2
Net cash outflow from investing activities	**–7,912**	**–2,293**	**>100**
Cash inflow from financing activities			
Payments from capital reductions/repurchase of treasury shares	0	–12,626	–100
Proceeds from the issuance of financial liabilities	49,932	19,891	>100
Payments from the repayment of financial liabilities	–48,839	–58,766	–16.9
Interest paid	–5,150	–7,723	–33.3
Repayments of lease liabilities	–3,863	–3,816	1.2
Net cash outflow from financing activities	**–7,919**	**–63,039**	**–87.4**
Net change in cash and cash equivalents	10,389	–12,668	<–100
Cash and cash equivalents at the beginning of the period	81,844	106,224	–23.0
Cash and cash equivalents at the end of the period	**92,234**	**93,556**	**–1.4**

Consolidated statement of changes in equity

in € thousand	Paid-in capital	Capital reserve	Accumulated consolidated net income	Treasury shares	Attributable to shareholders in the parent company	Equity
As of 01/01/2025	**25,506**	**406,283**	**78,403**	**0**	**510,192**	**510,192**
Net profit for 2025	0	0	19,912	0	19,912	19,912
Share-based payments	0	632	0	0	632	632
Capital Reduction	0	0	0	–12,626	–12,626	–12,626
As of 09/30/2025	**25,506**	**406,915**	**98,315**	**–12,626**	**518,110**	**518,110**
As of 01/01/2026	**25,506**	**407,525**	**93,768**	**–12,580**	**514,219**	**514,219**
Net profit 2026	0	0	12,771	0	12,771	12,771
Share-based payments	0	929	0	0	929	929
Equity-based compensation settled by issuing treasury shares	0	21	0	171	192	192
As of 09/30/2026	**25,506**	**408,475**	**106,539**	**–12,409**	**528,111**	**528,111**

This quarterly report was published on November 10, 2026.

Contact
Katrin Neuffer
Director of Investor Relations & Communications

Medios AG
Heidestrasse 9 | 10557 Berlin |Germany
T +49 30 232 566 832
Katrin.Neuffer@medios.group
www.medios.group

Disclaimer
This quarterly report contains forward-looking statements that are subject to certain risks and uncertainties. Future results may differ materially from those currently expected due to various risk factors and uncertainties, such as changes in the business, economic, and competitive environment; exchange rate fluctuations; uncertainties regarding legal disputes or investigations; and the availability of financial resources. Medios AG assumes no responsibility for updating the forward-looking statements contained in this quarterly report.